These revenues are for the anteobind sales for research purposes and not commercial sales, so when the partner commercialises their products they will most likely pay a licensing fee on top of anteobind purchases.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-43
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ADO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.2¢ |
Change
-0.002(8.33%) |
Mkt cap ! $54.31M | |||
| Open | High | Low | Value | Volume |
| 2.4¢ | 2.4¢ | 2.2¢ | $12.59K | 542.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 487271 | 2.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.3¢ | 200000 | 1 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| ADO (ASX) Chart |